{"id":"cyclosporine-emulsion","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Gingival hyperplasia"},{"rate":null,"effect":"Hirsutism"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response. The emulsion formulation improves bioavailability and absorption compared to conventional cyclosporine preparations.","oneSentence":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:41.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Organ transplant rejection prevention"},{"name":"Autoimmune conditions (e.g., rheumatoid arthritis, psoriasis)"}]},"trialDetails":[{"nctId":"NCT07368595","phase":"PHASE4","title":"Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Dry Eye Disease (DED)","enrollment":60},{"nctId":"NCT04795752","phase":"NA","title":"Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)","status":"COMPLETED","sponsor":"Sight Sciences, Inc.","startDate":"2021-04-28","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":345},{"nctId":"NCT06903884","phase":"PHASE3","title":"3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-12-30","conditions":"Vernal Keratoconjunctivitis","enrollment":94},{"nctId":"NCT07169695","phase":"PHASE2","title":"A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2026-03-02","conditions":"Moderate to Severe Vernal Keratoconjunctivitis","enrollment":120},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT04918823","phase":"PHASE1, PHASE2","title":"Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device","status":"COMPLETED","sponsor":"Boston Sight","startDate":"2021-07-15","conditions":"Ocular Surface Disease","enrollment":10},{"nctId":"NCT04144413","phase":"PHASE3","title":"3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-05-31","conditions":"Dry Eye Disease With Severe Keratitis","enrollment":350},{"nctId":"NCT04357795","phase":"PHASE4","title":"Effect of Cequa™ in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-06-29","conditions":"Dry Eye Disease","enrollment":135},{"nctId":"NCT04555694","phase":"PHASE4","title":"Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax","status":"COMPLETED","sponsor":"Thomas Chester, OD","startDate":"2020-10-01","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT00335114","phase":"NA","title":"Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2005-11","conditions":"Contact Lens Wearers With Dry Eye Syndrome","enrollment":40},{"nctId":"NCT04735510","phase":"PHASE3","title":"Novel Use of Restasis and PROSE Devices","status":"WITHDRAWN","sponsor":"Boston Sight","startDate":"2021-05","conditions":"Ocular Surface Disease","enrollment":""},{"nctId":"NCT04812951","phase":"EARLY_PHASE1","title":"Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2021-02-17","conditions":"Ocular Surface Disease, Ocular Inflammation","enrollment":101},{"nctId":"NCT04127851","phase":"PHASE4","title":"Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2019-11-12","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":438},{"nctId":"NCT01751126","phase":"PHASE3","title":"Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2013-04-29","conditions":"Vernal Keratoconjunctivitis","enrollment":169},{"nctId":"NCT05245604","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2020-06-19","conditions":"Dry Eye Syndrome","enrollment":182},{"nctId":"NCT00328653","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2006-05","conditions":"Conjunctivitis, Vernal","enrollment":118},{"nctId":"NCT03597139","phase":"PHASE2","title":"Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2018-08-13","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT04636918","phase":"PHASE4","title":"Ikervis for DED Due to GVHD Post Allo-HSCT","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2019-11-28","conditions":"Leukemia (Both ALL and AML), MDS-EB-1","enrollment":40},{"nctId":"NCT02004067","phase":"PHASE4","title":"Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2013-01","conditions":"Primary Sjogren Syndrome, Secondary Sjogren Syndrome, Aqueous Deficient Dry Eye Disease","enrollment":100},{"nctId":"NCT02199964","phase":"NA","title":"The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2014-03","conditions":"Dry Eye","enrollment":4},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT01817582","phase":"PHASE2","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05-17","conditions":"Keratoconjunctivitis Sicca","enrollment":102},{"nctId":"NCT00827255","phase":"","title":"Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Dry Eye Disease","enrollment":35},{"nctId":"NCT02121847","phase":"PHASE4","title":"Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT03666884","phase":"PHASE4","title":"The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Seref istek","startDate":"2015-10-10","conditions":"Dry Eye Syndrome","enrollment":36},{"nctId":"NCT02554981","phase":"PHASE4","title":"Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-07-21","conditions":"Dry Eye Syndromes","enrollment":51},{"nctId":"NCT00755040","phase":"PHASE3","title":"Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2008-10","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":164},{"nctId":"NCT01198782","phase":"PHASE4","title":"Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Dry Eye Syndrome","enrollment":48},{"nctId":"NCT02397213","phase":"PHASE2","title":"Ciclosporin to Protect Renal Function In Cardiac Surgery","status":"COMPLETED","sponsor":"Region Skane","startDate":"2015-04","conditions":"Acute Kidney Injury","enrollment":155},{"nctId":"NCT00739349","phase":"PHASE2","title":"NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2008-08","conditions":"Dry Eye","enrollment":132},{"nctId":"NCT01901471","phase":"PHASE2","title":"Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2015-09","conditions":"Acute Myocardial Infarction","enrollment":""},{"nctId":"NCT01319773","phase":"PHASE1","title":"Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Dry Eye Syndromes","enrollment":44},{"nctId":"NCT02461719","phase":"PHASE3","title":"Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2014-01","conditions":"Dry Eye Syndromes","enrollment":158},{"nctId":"NCT02114073","phase":"PHASE2","title":"Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure","status":"COMPLETED","sponsor":"Mashhad University of Medical Sciences","startDate":"2014-04","conditions":"Glaucoma, Open Angle","enrollment":40},{"nctId":"NCT01692834","phase":"PHASE1","title":"A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroVive Pharmaceutical AB","startDate":"2009-06","conditions":"Healthy","enrollment":65},{"nctId":"NCT00986427","phase":"PHASE2","title":"Restasis for Treatment of Brittle Nails","status":"COMPLETED","sponsor":"Julian M. Mackay-Wiggan","startDate":"2009-07","conditions":"Brittle Nails","enrollment":24},{"nctId":"NCT00371826","phase":"PHASE4","title":"SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":"Renal Transplanted Recipients","enrollment":126},{"nctId":"NCT00824811","phase":"PHASE2","title":"Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06","conditions":"Epiphora","enrollment":""},{"nctId":"NCT01109056","phase":"PHASE2","title":"Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Pterygium","enrollment":115},{"nctId":"NCT00717418","phase":"","title":"Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2004-09","conditions":"Keratoconjunctivitis Sicca","enrollment":781},{"nctId":"NCT00611403","phase":"PHASE2","title":"Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-12","conditions":"Dry Eye Syndromes","enrollment":137},{"nctId":"NCT00434590","phase":"PHASE4","title":"Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-03","conditions":"Kidney Transplantation","enrollment":10},{"nctId":"NCT00332462","phase":"PHASE4","title":"A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Liver Transplantation","enrollment":34},{"nctId":"NCT00150085","phase":"PHASE4","title":"Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion","status":"TERMINATED","sponsor":"Novartis","startDate":"2004-02","conditions":"Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients","enrollment":50},{"nctId":"NCT00705510","phase":"PHASE4","title":"Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-05","conditions":"Meibomian Gland Dysfunction","enrollment":70},{"nctId":"NCT00814515","phase":"PHASE3","title":"Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2007-09","conditions":"Moderate to Severe Dry Eye Syndrome","enrollment":482},{"nctId":"NCT00578370","phase":"PHASE1, PHASE2","title":"Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"ISDIN","startDate":"2007-11","conditions":"Psoriasis","enrollment":25},{"nctId":"NCT00349440","phase":"PHASE4","title":"Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2006-09","conditions":"Dry Eye Syndromes","enrollment":93},{"nctId":"NCT00706680","phase":"PHASE4","title":"Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2008-02","conditions":"Diabetes, Graft Rejection","enrollment":30},{"nctId":"NCT00704275","phase":"PHASE4","title":"Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2007-06","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT00001731","phase":"PHASE2","title":"Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1997-11","conditions":"Keratoconjunctivitis Sicca, Sjogren's Syndrome","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BURNING SENSATION"},{"count":1,"reaction":"DISCHARGE"},{"count":1,"reaction":"DISCOMFORT"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"HYPERSENSITIVITY"},{"count":1,"reaction":"LACRIMATION INCREASED"},{"count":1,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":1,"reaction":"THERAPEUTIC RESPONSE CHANGED"}],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cyclosporine emulsion","genericName":"Cyclosporine emulsion","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Dry eye disease, Organ transplant rejection prevention, Autoimmune conditions (e.g., rheumatoid arthritis, psoriasis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}